128 related articles for article (PubMed ID: 36095079)
21. Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis.
Yang X; Yang Y; Li Z; Cheng C; Yang T; Wang C; Liu L; Liu S
PLoS One; 2015; 10(4):e0124884. PubMed ID: 25894842
[TBL] [Abstract][Full Text] [Related]
22. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
[TBL] [Abstract][Full Text] [Related]
23. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
[TBL] [Abstract][Full Text] [Related]
24. A panel of 13 region-specific radioimmunoassays for measurements of human chromogranin B.
Stridsberg M; Eriksson B; Oberg K; Janson ET
Regul Pept; 2005 Feb; 125(1-3):193-9. PubMed ID: 15582732
[TBL] [Abstract][Full Text] [Related]
25. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.
Hijioka M; Ito T; Igarashi H; Fujimori N; Lee L; Nakamura T; Jensen RT; Takayanagi R
Cancer Sci; 2014 Nov; 105(11):1464-71. PubMed ID: 25220535
[TBL] [Abstract][Full Text] [Related]
26. Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Tian T; Gao J; Li N; Li Y; Lu M; Li Z; Lu Z; Li J; Shen L
PLoS One; 2016; 11(5):e0154679. PubMed ID: 27159453
[TBL] [Abstract][Full Text] [Related]
27. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
28. Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors.
Conlon JM
Regul Pept; 2010 Nov; 165(1):5-11. PubMed ID: 19931574
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies.
Molina R; Alvarez E; Aniel-Quiroga A; Borque M; Candás B; Leon A; Poyatos RM; Gelabert M
Tumour Biol; 2011 Feb; 32(1):13-22. PubMed ID: 20730520
[TBL] [Abstract][Full Text] [Related]
30. Chromogranin A as a Biochemical Marker for Neuroendocrine Tumors: A Single Center Experience at Royal Hospital, Oman.
Al-Risi ES; Al-Essry FS; Mula-Abed WS
Oman Med J; 2017 Sep; 32(5):365-370. PubMed ID: 29026467
[TBL] [Abstract][Full Text] [Related]
31. Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm.
Paik WH; Ryu JK; Song BJ; Kim J; Park JK; Kim YT; Yoon YB
J Korean Med Sci; 2013 May; 28(5):750-4. PubMed ID: 23678268
[TBL] [Abstract][Full Text] [Related]
32. Chromogranin B: isolation from pheochromocytoma, N-terminal sequence, tissue distribution and secretory vesicle processing.
Gill BM; Barbosa JA; Dinh TQ; Garrod S; O'Connor DT
Regul Pept; 1991 Apr; 33(2):223-35. PubMed ID: 1882087
[TBL] [Abstract][Full Text] [Related]
33. Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors.
Cui T; Hurtig M; Elgue G; Li SC; Veronesi G; Essaghir A; Demoulin JB; Pelosi G; Alimohammadi M; Öberg K; Giandomenico V
PLoS One; 2010 Dec; 5(12):e16010. PubMed ID: 21209860
[TBL] [Abstract][Full Text] [Related]
34. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
35. Chromogranin A: is it a useful marker of neuroendocrine tumors?
Campana D; Nori F; Piscitelli L; Morselli-Labate AM; Pezzilli R; Corinaldesi R; Tomassetti P
J Clin Oncol; 2007 May; 25(15):1967-73. PubMed ID: 17513802
[TBL] [Abstract][Full Text] [Related]
36. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
[TBL] [Abstract][Full Text] [Related]
37. A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors.
Modlin IM; Aslanian H; Bodei L; Drozdov I; Kidd M
Endocr Connect; 2014 Dec; 3(4):215-23. PubMed ID: 25316294
[TBL] [Abstract][Full Text] [Related]
38. Cellular expression and specific intragranular localization of chromogranin A, chromogranin B, and synaptophysin during ontogeny of pancreatic islet cells: an ultrastructural study.
Lukinius A; Stridsberg M; Wilander E
Pancreas; 2003 Jul; 27(1):38-46. PubMed ID: 12826904
[TBL] [Abstract][Full Text] [Related]
39. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role.
Cimitan M; Buonadonna A; Cannizzaro R; Canzonieri V; Borsatti E; Ruffo R; De Apollonia L
Ann Oncol; 2003 Jul; 14(7):1135-41. PubMed ID: 12853358
[TBL] [Abstract][Full Text] [Related]
40. A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms.
Kruljac I; Vurnek I; Maasberg S; Kust D; Blaslov K; Ladika Davidović B; Štefanović M; Demirović A; Bišćanin A; Filipović-Čugura J; Marić Brozić J; Pape UF; Vrkljan M
Endocrine; 2018 Jun; 60(3):395-406. PubMed ID: 29633144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]